Journal of Rheumatology

Hyperferritinemia wins again: Defining macrophage activation syndrome in pediatric systemic lupus erythematosus.  48:1355-1357. 2021

What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout. 2021

Biologic switching among nonsystemic juvenile idiopathic arthritis patients: A cohort study in the childhood arthritis and rheumatology research alliance registry.  48:1322-1329. 2021

Drs. Cron and Chatham reply.  48:1345-1346. 2021

Maintaining hepatitis B protection in immunocompromised pediatric rheumatology and inflammatory bowel disease patients.  48:1314-1321. 2021

Meaningful change thresholds for patient-reported outcomes measurement information system (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis.  48:1239-1242. 2021

Anca-Associated vasculitis management in the united states: Data from the rheumatology informatics system for effectiveness (rise) registry.  48:1060-1064. 2021

Aotearoa New Zealand Māori and Pacific Population-amplified Gout Risk Variants: CLNK Is a Separate Risk Gene at the SLC2A9 Locus. 2021

Evaluation of the Effect of Diabetes on Rheumatoid Arthritis-related Outcomes in an Electronic Health Record-based Rheumatology Registry.  48:992-1001. 2021

Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death. 2021

Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs.  48:804-812. 2021

Hospitalized infections in people with osteoarthritis: A national US study.  48:933-939. 2021

Time trends in opioid use disorder hospitalizations in gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, and low back pain.  48:775-784. 2021

Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic.  48:603-607. 2021

When has a knee or hip replacement failed? a patient perspective.  48:447-453. 2021

Flare rate thresholds for patient assessment of disease activity states in Gout.  48:293-298. 2021

Phenylalanine is a novel marker for radiographic knee osteoarthritis progression: The MOST study.  48:123-128. 2021

Variability in urate-lowering therapy prescribing: A gout, hyperuricemia and crystal-associated disease network (G-CAN) physician survey.  48:152-153. 2021

Do serum urate-associated genetic variants influence gout risk in people taking diuretics? Analysis of the UK biobank.  47:1704-1711. 2020

Drs. cron and chatham reply.  47:1723. 2020

Psychological and pain sensitization characteristics are associated with patellofemoral osteoarthritis symptoms: The multicenter osteoarthritis study.  47:1696-1703. 2020

Drs. Cron and Chatham reply.  47:1590-1591. 2020

Quality of care in childhood-onset systemic lupus erythematosus: Report of an intervention to improve cardiovascular and bone health screening.  47:1506-1513. 2020

Scope of outcomes in trials and observational studies of interventions targeting medication adherence in rheumatic conditions: A systematic review.  47:1565-1574. 2020

How systemic sclerosis affects healthcare use and complication rates after total hip arthroplasty.  47:1218-1223. 2020

Sleep quality is related to worsening knee pain in those with widespread pain: The multicenter osteoarthritis study.  47:1019-1025. 2020

The Rheumatologist's Role in COVID-19.  47:639-642. 2020

Diffuse Idiopathic Skeletal Hyperostosis in Smokers and Restrictive Spirometry Pattern: An Analysis of the COPDGene Cohort.  47:531-538. 2020

Insurance Payer Type and Patient Income Are Associated with Outcomes after Total Shoulder Arthroplasty.  47:589-596. 2020

Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Affairs gout cohort.  47:449-460. 2020

Construction of a frailty index as a novel health measure in systemic lupus erythematosus.  47:72-81. 2020

Fatigue measurements in systemic lupus erythematosus.  46:1470-1477. 2019

Addressing challenges in developing a core domain set in adherence interventions in rheumatology: A report from the OMERACT-Adherence Group.  46:1202-1206. 2019

Identifying provisional generic contextual factor domains for clinical trials in rheumatology: Results from an OMERACT initiative.  46:1159-1163. 2019

Rates of total joint replacement in the United States: Future projections to 2020-2040 using the national inpatient sample.  46:1134-1140. 2019

Core domain Set selection according to OMERACT filter 2.1: The OMERACT methodology.  46:1014-1020. 2019

Establishing an updated core domain set for studies in juvenile idiopathic arthritis: A report from the OMERACT 2018 JIA workshop.  46:1006-1013. 2019

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT premeeting toward consensus on core sets for randomized controlled trials.  46:1053-1058. 2019

Instrument selection using the OMERACT filter 2.1: The OMERACT methodology.  46:1028-1035. 2019

OMERACT filter 2.1: Elaboration of the conceptual framework for outcome measurement in health intervention studies.  46:1021-1027. 2019

The Third Biennial 2018 OMERACT First-time Participant Program: A qualitative and quantitative study.  46:1036-1040. 2019

Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States.  46:237-244. 2019

HLA-DRB1 amino acid positions and residues associated with antibody-positive rheumatoid arthritis in black south africans.  46:138-144. 2019

Fertility and ovarian reserve among women with rheumatoid arthritis.  46:455-459. 2019

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.  46:1409-1414. 2019

Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.  46:492-500. 2019

Pain measurement in rheumatic and musculoskeletal diseases: Where to go from here? Report from a special interest group at OMERACT 2018.  46:355-1359. 2019

Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor.  46:475-482. 2019

Predictors of remission and low disease activity state in systemic lupus erythematosus: Data from a multiethnic, multinational Latin American cohort.  46:1299-1308. 2019

Standardizing terminology and assessment for orofacial conditions in juvenile idiopathic arthritis: International, multidisciplinary consensus-based recommendations.  46:518-522. 2019

Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in Juvenile idiopathic arthritis.  45:1301-1307. 2018

Adiposity in juvenile psoriatic arthritis.  45:411-418. 2018

Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus.  45:393-396. 2018

Variability in the reporting of serum urate and flares in gout clinical trials: Need for minimum reporting requirements.  45:419-424. 2018

Trends in joint replacement surgery in patients with rheumatoid arthritis.  45:158-164. 2018

Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritis.  45:40-44. 2018

Critical outcomes in longitudinal observational studies and registries in patients with rheumatoid arthritis: An OMERACT special interest group report.  44:1894-1898. 2017

Evidence for updating the core domain set of outcome measures for juvenile idiopathic arthritis: Report from a special interest group at OMERACT 2016.  44:1884-1888. 2017

Validating rheumatoid arthritis remission using the patients' perspective: Results from a special interest group at OMERACT 2016.  44:1889-1893. 2017

Achieving consensus on total joint replacement trial outcome reporting using the OMERACT filter: Endorsement of the final core domain set for total hip and total knee replacement trials for endstage arthritis.  44:1723-1726. 2017

Health equity considerations for developing and reporting patient-reported outcomes in clinical trials: A report from the omeract equity special interest group.  44:1727-1733. 2017

Isolated arthritis of the temporomandibular joint as the initial manifestation of juvenile idiopathic arthritis.  44:1632-1635. 2017

Engaging stakeholders and promoting uptake of OMERACT core outcome instrument sets.  44:1551-1559. 2017

Malignancy in pediatric-onset systemic lupus erythematosus.  44:1484-1486. 2017

The OMERACT first-time participant program: Fresh eye from the new guys.  44:1560-1563. 2017

Outcome measures used in arthroplasty trials: Systematic review of the 2008 and 2013 literature.  44:1277-1287. 2017

Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases.  44:1083-1087. 2017

Weathering a macrophage storm.  44:970-972. 2017

Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis c virus infection.  44:565-570. 2017

The effect of widespread pain on knee pain worsening, incident knee osteoarthritis (OA), and incident knee pain: The multicenter OA (MOST) study.  44:493-498. 2017

Clinical orofacial examination in juvenile idiopathic arthritis: International consensus-based recommendations for monitoring patients in clinical practice and research studies.  44:326-333. 2017

The juvenile psoriatic arthritis cohort in the CARRA registry: Clinical characteristics, classification, and outcomes.  44:342-351. 2017

Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic review.  43:1997-2009. 2016

Treatments for lupus nephritis: A systematic review and network metaanalysis.  43:1801-1815. 2016

Time trends, predictors, and outcome of emergency department use for gout: A nationwide US study.  43:1581-1588. 2016

Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry.  43:1027-1029. 2016

Prospecting for precision: Promises for personalized medicine.  43:999-1000. 2016

Ms. A.M. Taylor, et al reply.  43:826. 2016

The performance and association between patient-reported and performance-based measures of physical functioning in research on individuals with arthritis.  43:131-137. 2016

Imaging as an outcome measure in gout studies: Report from the OMERACT gout working group.  42:2460-2464. 2015

Outcome domains and measures in total joint replacement clinical trials: Can we harmonize them? An OMERACT collaborative initiative.  42:2496-2502. 2015

Toward ensuring health equity: Readability and cultural equivalence of OMERACT patient-reported outcome measures.  42:2448-2459. 2015

Consensus on the need for a hierarchical list of patient-reported pain outcomes for metaanalyses of knee osteoarthritis trials: An OMERACT objective.  42:1971-1975. 2015

Current state of reporting pain outcomes in cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda.  42:1934-1942. 2015

Harmonizing pain outcome measures: Results of the pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the cochrane musculoskeletal group and OMERACT.  42:1943-1946. 2015

Is chronic pain a disease in its own right? Discussions from a pre-OMERACT 2014 workshop on chronic pain.  42:1947-1953. 2015

No association between daily walking and knee structural changes in people at risk of or with mild knee osteoarthritis. prospective data from the multicenter osteoarthritis study.  42:1685-1693. 2015

A call for evidence-based decision making when selecting outcome measurement instruments for summary of findings tables in systematic reviews: Results from an OMERACT working group.  42:1954-1961. 2015

An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users.  42:1478-1483. 2015

Barriers to medication decision making in women with lupus nephritis: A formative study using nominal group technique.  42:1616-1623. 2015

Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.  42:994-1001. 2015

Do "evidence-based recommendations" need to reveal the evidence? Minimal criteria supporting an "evidence claim".  42:1737-1739. 2015

Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?.  42:1078-1080. 2015

Is the double contour sign specific for gout? Or only for crystal arthritis?.  42:353-354. 2015

Magnetic resonance imaging findings following intraarticular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritis.  42:2155-2159. 2015

Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.  42:504-512. 2015

Optimal strategies for reporting pain in clinical trials and systematic reviews: Recommendations from an OMERACT 12 workshop.  42:1962-1970. 2015

Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.  42:541-546. 2015

The OMERACT first-time participant ("Newbie") program: Initial assessment and lessons learned.  42:1976-1981. 2015

Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.  41:1935-1943. 2014

Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.  41:2078-2084. 2014

Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.  41:216-226. 2014

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.  41:300-309. 2014

Update of strategies to translate evidence from cochrane musculoskeletal group systematic reviews for use by various audiences.  41:206-215. 2014

Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses.  41:194-205. 2014

American college of rheumatology criteria at inception, and accrual over 5 years in the slicc inception cohort.  41:875-880. 2014

Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.  41:574-580. 2014

Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.  41:113-118. 2014

Does clinically important change in function after knee replacement guarantee good absolute function? the multicenter osteoarthritis study.  41:60-64. 2014

How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.  41:1025-1030. 2014

Including health equity considerations in development of instruments for rheumatology research: An introduction to a novel OMERACT paradigm.  41:150-152. 2014

Introduction: OMERACT 11 - International consensus conference on outcome measures in rheumatology clinical trials.  41:145-149. 2014

OMERACT endorsement of measures of outcome for studies of acute gout.  41:569-573. 2014

Outcome measures in acute gout: A systematic literature review.  41:558-568. 2014

Reliability and clinically important improvement thresholds for osteoarthritis pain and function scales: A multicenter study.  41:509-515. 2014

Research priorities in gout: The patient perspective.  41:615-616. 2014

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-Label, longterm extension studies.  41:837-852. 2014

The diagnostic performance of anterior knee pain and activity-related pain in identifying knees with structural damage in the patellofemoral joint: The Multicenter Osteoarthritis Study.  41:1695-1702. 2014

Updating the OMERACT Filter: Core areas as a basis for defining core outcome sets.  41:994-999. 2014

Updating the OMERACT filter: Implications for imaging and soluble biomarkers.  41:1016-1024. 2014

Updating the omeract filter: Discrimination and feasibility.  41:1005-1010. 2014

Updating the omeract filter: Implications of filter 2.0 to select outcome instruments through assessment of "truth": Content, face, and construct validity.  41:1000-1004. 2014

Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis.  40:1812-1822. 2013

Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfect.  40:1640-1642. 2013

High doses of infliximab in the management of juvenile idiopathic arthritis.  40:1749-1755. 2013

A Delphi exercise to identify characteristic features of gout - Opinions from patients and physicians, the first stage in developing new classification criteria (Journal of Rheumatology (2013) 40, (498-505)).  40:1634. 2013

Associations of alcohol use with radiographic disease progression in African Americans with recent-onset rheumatoid arthritis.  40:1498-1504. 2013

Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009.  40:1218-1225. 2013

Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry.  40:842-849. 2013

Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trial.  40:572-578. 2013

Higher-dose anakinra is effective in a case of medically refractory macrophage activation syndrome.  40:743-744. 2013

A Delphi exercise to identify characteristic features of gout - Opinions from patients and physicians, the first stage in developing new classification criteria.  40:498-505. 2013

Shrinking lung syndrome as a manifestation of pleuritis: A new model based on pulmonary physiological studies.  40:273-281. 2013

Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.  40:127-136. 2013

Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis.  39:1880-1887. 2012

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.  39:1632-1640. 2012

Genetic risk factors for thrombosis in systemic lupus erythematosus.  39:1603-1610. 2012

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials.  39:1450-1457. 2012

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trial.  39:1326-1333. 2012

Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: Enthesitis-related arthritis predicts persistent active disease.  38:2675-2681. 2011

Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis.  38:2274-2275. 2011

Temporomandibular joint arthritis in pediatric Sjögren disease and sarcoidosis.  38:2272-2273. 2011

Smoking and outcomes after knee and hip arthroplasty: A systematic review.  38:1824-1834. 2011

Arthritis increases the risk for fractures - Results from the women's health initiative.  38:1680-1688. 2011

Developing a construct to evaluate flares in rheumatoid arthritis: A conceptual report of the OMERACT RA Flare Definition Working Group.  38:1745-1750. 2011

Bringing it all together: A novel approach to the development of response criteria for chronic gout clinical trials.  38:1467-1470. 2011

Consistency of knee pain and risk of knee replacement: The multicenter osteoarthritis study.  38:1390-1395. 2011

Early postoperative mortality following joint arthroplasty: A systematic review.  38:1507-1513. 2011

Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: A randomized controlled trial (The Journal of Rheumatology (2010) 37, (2377-86)).  38:1534. 2011

Patient-reported outcomes in chronic gout: A report from OMERACT 10.  38:1452-1457. 2011

Serum urate in chronic gout - Will it be the first validated soluble biomarker in rheumatology?.  38:1462-1466. 2011

Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities.  38:1458-1461. 2011

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial.  38:990-996. 2011

An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.  38:764-768. 2011

Surgery for shoulder osteoarthritis: A cochrane systematic review.  38:598-605. 2011

Botulinum toxin for shoulder pain: A cochrane systematic review.  38:409-418. 2011

The functional polymorphism 844 A>G in Fc αRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility.  38:446-449. 2011

Disease phenotypes and gender association of FCRL3 single-nucleotide polymorphism -169T/C in Taiwanese patients with systemic lupus erythematosus and rheumatoid arthritis.  38:264-270. 2011

Combination therapy of abatacept and in children with refractory systemic juvenile idiopathic arthritis: A retrospective case series.  38:180-181. 2011

Tocilizumab for rheumatoid arthritis: A cochrane systematic review.  38:10-20. 2011

Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: A randomized controlled trial.  37:2377-2386. 2010

Spondyloarthritis in a pediatric population: Risk factors for sacroiliitis.  37:2402-2408. 2010

Clinically important improvement in function is common in people with or at high risk of knee OA: The MOST study.  37:1244-1251. 2010

Golimumab for rheumatoid arthritis: A systematic review.  37:1096-1104. 2010

Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: Comparison of 2 initial dosing regimens.  37:870-875. 2010

(Journal of Rheumatology (2009) 36, (2114) DOI:10.3899/jrheum.090591).  37:681. 2010

Abatacept for rheumatoid arthritis: A cochrane systematic review (Journal of Rheumatology (2010) 37, (234-245) DOI:10.3899/jrheum.091066).  37:682. 2010

Vitamin D status and its associations with disease activity and severity in african americans with recent-onset rheumatoid arthritis.  37:275-281. 2010

A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.  37:167-174. 2010

Abatacept for rheumatoid arthritis: A cochrane systematic review.  37:234-245. 2010

Assessment of the methodologic quality of medical and surgical clinical trials in patients with arthroplasty.  36:2642-2654. 2009

What makes patients with fibromyalgia feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: A pooled analysis of 4 randomized placebo-controlled trials of duloxetine.  36:2517-2522. 2009

Assessing single joints in arthritis clinical trials.  36:2092-2096. 2009

Discordance between self-report of physician diagnosis and administrative database diagnosis of arthritis and its predictors.  36:2000-2008. 2009

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial.  36:1705-1714. 2009

Anakinra for rheumatoid arthritis: A systematic review.  36:1118-1125. 2009

Spondyloarthritis is associated with poor function and physical health-related quality of life.  36:1012-1020. 2009

Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis.  36:106-112. 2009

Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity.  36:82-88. 2009

How to ascertain drug safety in the context of benefit. Controversies and concerns.  36:2114-2121. 2009

Evaluation of an instrument assessing influence of gout on health-related quality of life.  35:2406-2414. 2008

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage.  35:2355-2358. 2008

A new approach yields high rates of radiographic progression in knee osteoarthritis.  35:2047-2054. 2008

Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).  35:343-348. 2008

Neither cell-surface nor soluble CD154 levels are associated with coronary artery disease in systemic lupus erythematosus.  35:359-360. 2008

Does medical insurance matter in the progression to endstage renal disease among patients with lupus nephritis?.  34:1953-1954. 2007

Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.  34:1133-1138. 2007

Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software [3].  34:234. 2007

Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis.  33:2330-2336. 2006

Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis.  33:2081-2084. 2006

Trends in prevention of glucocorticoid-induced osteoporosis.  33:1651-1657. 2006

Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-α therapy [1].  33:825. 2006

Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting system.  33:562-566. 2006

Treatment of pediatric localized scleroderma with methotrexate.  33:609-614. 2006

Patterns of use and public perception of over-the-counter pain relievers: Focus on nonsteroidal antiinflammatory drugs.  32:2218-2224. 2005

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.  32:2150-2155. 2005

Pain-related beliefs and affective pain responses: Implications for ethnic disparities in preferences for joint arthroplasty.  32:1149-1152. 2005

Effect of ethnicity on disease activity in systemic lupus erythematosus [1] (multiple letters).  32:962-963. 2005

Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture.  32:870-875. 2005

Swallowing difficulties from "DISH-phagia".  31:2526-2527. 2004

The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.  31:1934-1940. 2004

Effect of methotrexate therapy on bone mineral density and body composition in rat adjuvant arthritis.  31:1693-1697. 2004

Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid- naïve patients.  31:1281-1285. 2004

Recent Approaches to Understanding Osteoarthritis Pain.  31:54-60. 2004

Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety Practices.  30:2680-2688. 2003

A 2-Phase Screening Process for Patients with Wegener's Granulomatosis: A Pilot Study.  30:2420-2421. 2003

Health related quality of life in women with elderly onset rheumatoid arthritis.  30:952-957. 2003

OMERACT 6 brings new perspectives to rheumatology measurement research.  30:639-641. 2003

Balancing bones and bucks among new glucocorticoid users.  30:1-3. 2003

Normal radiographs in patients with persistent "hip pain" - Value of magnetic resonance imaging.  29:2463-2465. 2002

Significance of increased circulating proteasome in autoimmune disease.  29:2027-2030. 2002

Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women.  29:246-254. 2002

Absence of linkage or association for osteoarthritis with the vitamin D receptor/type II collagen locus: The Framingham Osteoarthritis Study.  29:161-165. 2002

MTX affects inflammation and tissue destruction differently in the rat AA model.  28:1476-1481. 2001

Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort.  28:1298-1305. 2001

Women in rheumatology [1].  28:1735-1736. 2001

Occurrence of scleroderma in monozygotic twins.  27:2267-2269. 2000

The impact of women in the practice of academic and clinical rheumatology in the Americas.  27:1827-1829. 2000

Nabumetone induced pseudoporphyria in childhood [3] (multiple letters).  27:1817-1818. 2000

Nabumetone induced pseudoporphyria in childhood..  27:1817-1818. 2000

Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis.  27:1038-1044. 2000

Radiographic assessment of disease progression in rheumatoid arthritis patients treated with methotrexate or minocycline.  27:530-534. 2000

Expression of the precursor of secretoneurin, secretogranin II, in the synovium of patients with rheumatoid arthritis and osteoarthritis.  27:2347-2350. 2000

Current treatment by United States and Canadian pediatric rheumatologists.  26:2036-2038. 1999

Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug [1] (multiple letters).  26:2280-2281. 1999

Self-administered joint counts and standard joint counts in the assessment of rheumatoid arthritis.  26:1065-1067. 1999

Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: Disease remissions and changes in diagnoses in well established and undifferentiated CTD.  26:816-825. 1999

Self-administered joint counts in rheumatoid arthritis: Comparison with standard joint counts.  26:536-539. 1999

Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug.  26:259-261. 1999

Folic acid supplementation prevents deficient blood [1] (multiple letters).  25:2473. 1998

Familial painful restless legs syndrome correlates with pain dependent variation of blood flow to the caudate, thalamus, and anterior cingulate gyrus.  25:2270-2275. 1998

Enhanced expression of immunoglobulin κ light chains with unusually long CDR3 regions in patients with rheumatoid arthritis.  25:1067-1071. 1998

Septic arthritis caused by Neisseria sicca..  25:826-828. 1998

Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention.  25:441-446. 1998

Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: Disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases.  25:261-268. 1998

Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.  25:221-228. 1998

A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial.  24:1910-1915. 1997

Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone..  24:1849-1850. 1997

Childhood sarcoidosis--does age of onset predict clinical manifestations?.  24:1654-1656. 1997

Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) trial.  24:1295-1302. 1997

Folinic acid to prevent side effects of methotrexate in juvenile rheumatoid arthritis [3].  23:2184-2185. 1996

Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis.  23:1849-1855. 1996

Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis.  23:1845-1848. 1996

Vβ17 T cell receptor peptide vaccination in rheumatoid arthritis: Results of phase I dose escalation study.  23:1353-1362. 1996

Systemic lupus erythematosus: Predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: Multivariate analyses and identification of risk factors.  23:469-475. 1996

Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly.  22:2142-2147. 1995

Reiter's syndrome associated with cryptosporidial gastroenteritis.  22:1962-1963. 1995

Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus.  21:1457-1462. 1994

Arthroscopic evaluation of knee articular cartilage: A comparison with plain radiographs and magnetic resonance imaging.  21:675-679. 1994

Survival impact of autoantibodies in systemic lupus erythematosus.  21:224-228. 1994

Functional magnetic resonance imaging should be included in the evaluation of the cervical spine in patients with rheumatoid arthritis.  20:1485-1488. 1993

Meta analysis of the effect of methotrexate on radiologic progression in rheumatoid arthritis [1].  20:1623. 1993

Anticardiolipin antibodies in systemic lupus erythematosus: Clinical correlates, HLA associations, and impact on survival.  20:1684-1693. 1993

Folic acid supplementation during methotrexate therapy: It makes sense.  20:929-930. 1993

Sternoclavicular brucellar arthritis: A report of 7 cases and a review of the literature.  20:1184-1186. 1993

Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: A meta-analysis.  19:1868-1873. 1992

Digital subtraction radiography for the assessment of bone changes in rheumatoid arthritis.  19:1697-1703. 1992

Expressing our inner thoughts: How to organize and write a clinical research project grant application.  19:16-19. 1992

Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.  19:1207-1211. 1992

Mechanisms of pathogenesis in scleroderma. II. Effects of serum and conditioned culture medium on fibroblast function in scleroderma.  19:1212-1219. 1992

Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia.  19:1191-1194. 1992

Subcutaneous pancreatic fat necrosis associated with acute arthritis.  19:630-632. 1992

Disease and psychosocial factors related to physical functioning in rheumatoid arthritis.  18:1150-1157. 1991

Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease.  18:1332-1339. 1991

Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases.  18:1340-1343. 1991

Monthly cyclophosphamide in lupus pneumonitis and myositis.  18:153. 1991

Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?.  18:984-988. 1991

Activated lymphocytes in peripheral blood of patients with RA.  17:1712. 1990

An eosinophilia-myalgia syndrome associated with an L-tryptophan containing product.  17:1551-1553. 1990

Eosinophilic myositis an expression of L-tryptophan toxicity?.  17:1554-1556. 1990

Mortality vs quality of life (I).  17:1110. 1990

The value of the Norgaard view in the evaluation of erosive arthritis.  17:614-617. 1990

Cognitive-behavioral therapy for primary fibromyalgia.  16:131-136. 1989

Discriminant and convergent validity of self-report measures of affective distress in patients with rheumatoid arthritis.  16:1428-1432. 1989

Thrombotic thrombocytopenic purpura in systemic sclerosis..  16:1400-1401. 1989

AS and a 9.2 kb Pvu II class I HLA DNA restriction fragment..  16:141-142. 1989

Clinical characteristics affecting survival in patients with rheumatoid arthritis undergoing cervical spine surgery: A controlled study.  16:890-896. 1989

Lupus pneumonitis and anti-SSA(Ro) antibodies.  16:479-481. 1989

Methotrexate-induced liver abnormalities in rheumatoid arthritis.  16:1180-1183. 1989

Rheumatoid arthritis in American blacks: A clinical and radiological study.  16:1197-1200. 1989

Septic arthritis due to Mycobacterium phlei presenting as infantile Reiter's syndrome.  16:1377-1378. 1989

Severe reversible interstitial pneumonitis induced by low dose methotrexate.  16:1007-1008. 1989

Articular involvement in human brucellosis..  15:379-380. 1988

Etiopathogenesis of rheumatoid arthritis-like disease in MRL/1 mice: II. Ultrastructural basis of joint destruction.  15:10-16. 1988

The value of the joint alignment and motion scale in rheumatoid arthritis.  15:1212-1215. 1988

Transient osteoporosis of the hip: Magnetic resonance imaging.  14:1184-1189. 1988

The arthritis of brucellosis: a perspective one hundred years after Bruce's discovery..  14:1083-1085. 1987

The assessment of pain in rheumatoid arthritis: Disease differentiation and temporal stability of a behavioral observation method.  14:700-704. 1987

Sexual quality-of-life of patients with arthritis compared to arthritis-free controls.  14:570-576. 1987

Toxicity to methotrexate in rheumatoid arthritis.  14:74-79. 1987

Genetic and molecular genetic studies of murine and human lupus..  14 Suppl 13:166-176. 1987

Toxicity due to remission inducing drugs in RA..  14:175-176. 1987

Development of clinical criteria for osteoarthritis.  14:3-6. 1987

Evaluation of the American Rheumatism Association preliminary criteria for remission in rheumatoid arthritis: A prospective study.  14:93-96. 1987

Meeting highlights: Workshop on epidemiology of the rheumatic diseases in the Americas.  13:810-813. 1986

Tuberculous podagra..  12:1022-1024. 1985

Paracoccidioides brasiliensis arthritis. Report of a case and review of the literature.  12:356-358. 1985

The carpometacarpal ratio: A useful method for assessing disease progression in rheumatoid arthritis.  12:846-848. 1985

Study of HLA antigens in ten multiple-case rheumatoid arthritis families.  11:129-135. 1984

Local synthesis of IgM and IgM rheumatoid factor in rheumatoid pleuritis.  10:204-209. 1983

DR antigen distribution in blacks with rheumatoid arthritis.  10:579-583. 1983

Reactive arthritis associated with brucellosis: HAL studies.  8:621-625. 1981